Martingale Asset Management’s Aerie Pharmaceuticals AERI Stock Holding History

Martingale Asset Management’s Portfolio AERI Stock Details AERI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-38,299	Closed	-$580K	–	903
2022 Q3	$580K	Buy	+38,299	New	+$445K	0.01%	587
2021 Q4	–	Sell	-32,718	Closed	-$374K	–	911
2021 Q3	$374K	Buy	+32,718	New	+$478K	﹤0.01%	719

Martingale Asset Management's AERI Position: Q4 2022 in Review

Martingale Asset Management sold out of Aerie Pharmaceuticals (AERI) in Q4 2022, closing a stake of 38,299 shares — an estimated $580K sold.

Martingale Asset Management first reported a position in AERI in Q3 2021 and held it in 2 quarters. The position peaked at $580K in Q3 2022. 0 funds tracked by Wall St. Rank hold AERI as of Q4 2022.

Martingale Asset Management reported no remaining Aerie Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
Martingale Asset Management sold 38,299 Aerie Pharmaceuticals shares in Q4 2022, an estimated $580K.
Martingale Asset Management first reported a position in Aerie Pharmaceuticals in Q3 2021 and held it in 2 quarters.
Martingale Asset Management's Aerie Pharmaceuticals position peaked at $580K in Q3 2022.
0 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q4 2022.

Based on Martingale Asset Management's 13F filing for Q4 2022, filed 13 Feb 2023.